These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21089112)

  • 21. Culprit coronary lesions requiring percutaneous coronary intervention after vascular surgery often arise from in-stent restenosis of bare metal stents.
    Garcia S; Murray ST; Moritz TE; Pierpont G; Goldman S; Larsen GC; Littooy F; Ward HB; McFalls EO
    Ann Vasc Surg; 2010 Jul; 24(5):596-601. PubMed ID: 20579583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study.
    Hage C; Norhammar A; Grip L; Malmberg K; Sarkar N; Svane B; Rydén L
    Diab Vasc Dis Res; 2009 Apr; 6(2):71-9. PubMed ID: 20368196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
    Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
    Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.
    Fang CC; Ng Jao YT; Yi-Chen ; Yu CL; Chen CL; Wang SP
    Angiology; 2007; 58(5):523-34. PubMed ID: 18024934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis.
    L'Allier PL; Tardif JC; Grégoire J; Joyal M; Lespérance J; Fortier A; Guertin MC
    Can J Cardiol; 2005 May; 21(6):495-500. PubMed ID: 15917878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T
    Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does a well developed collateral circulation predispose to restenosis after percutaneous coronary intervention? An intravascular ultrasound study.
    Perera D; Postema P; Rashid R; Patel S; Blows L; Marber M; Redwood S
    Heart; 2006 Jun; 92(6):763-7. PubMed ID: 16216859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QT Dispersion and Age; Independent Predictors of Restenosis after Percutaneous Coronary Intervention.
    Aslanabadi N; Moghadam SV; Kazemi B; Fouladi DF; Vaseghi G; Eshraghi A; Mahmoodian M; Tutunchi S
    Rev Recent Clin Trials; 2017; 12(1):38-43. PubMed ID: 27633966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
    Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
    J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
    Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
    J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provisional stenting for multivessel PCI.
    Han B; Liu L; Aboud M; Nahir M; Hasin Y
    Int J Cardiovasc Intervent; 2005; 7(1):46-51. PubMed ID: 16019615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
    Colhoun HM; Betteridge DJ; Durrington P; Hitman G; Neil A; Livingstone S; Charlton-Menys V; Bao W; Demicco DA; Preston GM; Deshmukh H; Tan K; Fuller JH
    Diabetes; 2011 Sep; 60(9):2379-85. PubMed ID: 21771973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis.
    Saleh N; Tornvall P
    Atherosclerosis; 2007 Dec; 195(2):374-8. PubMed ID: 17126343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.